中国防痨杂志 ›› 2014, Vol. 36 ›› Issue (9): 830-854.doi: 10.3969/j.issn.1000-6621.2014.09.017
中国防痨协会结核病临床专业委员会
收稿日期:
2014-06-07
出版日期:
2014-09-10
发布日期:
2014-11-28
通信作者:
唐神结;刘一典
E-mail:tangsj1106@sina.com;liuyidian115@sina.com
Clinic Society of Chinese Antituberculosis Association
Received:
2014-06-07
Online:
2014-09-10
Published:
2014-11-28
Contact:
TANG Shen-jie;LIU Yi-dian
E-mail:tangsj1106@sina.com;liuyidian115@sina.com
摘要: 2013年在结核病临床治疗方面国内外取得了一些进展。以贝达喹啉为首的新药得到了进一步的临床应用。疫苗的研究在纳米技术、佐剂方面有新的尝试;口服制剂V7的免疫治疗初步报告结果显示,其具有一定应用前景。报道肯定了经支气管镜球囊扩张术对结核性支气管狭窄进行介入治疗方面的作用;胸腔镜治疗结核性包裹性胸腔积液的疗效满意。耐多药肺结核患者选择适当的手术指征,手术治疗疗效满意。耐药骨关节结核需要在个体化治疗的基础上,制定个体化手术方案。标准化方案治疗耐多药结核病具有一定效果,含莫西沙星方案可能优于左氧氟沙星方案,而含第5组药物化疗方案的疗效还需要更多的观察。对HIV感染者进行异烟肼预防性抗结核治疗得到WHO推荐,合并结核病的HIV感染者推荐在标准方案的基础上继续异烟肼治疗6月以上,以防止复发。老年结核病患者所占比例大,其抗结核治疗方案宜充分考虑药物的不良反应及患者的基础疾病和合并用药,慎用氨基糖苷类抗结核药,适当选用二线药物,并注意调整剂量。儿童结核病的资料严重不足,不仅缺乏诊断的有效手段,而且感染结核分枝杆菌后患儿病情进展迅速,应加以重视。孕期如使用抗结核药物,除了链霉素之外,其余一线抗结核药都是安全的,短程化疗对于妊娠结核病治疗有效,而且致畸作用和肝毒性并未得到证实。药物性肝损伤是抗结核药物最常见的不良反应,中华医学会结核病学分会于2013年撰写了《抗结核药所致药物性肝损伤诊断与处理专家建议》,是年度重要进展;而对于预防性保肝治疗,意见尚不统一。
中国防痨协会结核病临床专业委员会. 结核病临床诊治进展年度报告(2013年) (第二部分 结核病临床治疗)[J]. 中国防痨杂志, 2014, 36(9): 830-854. doi: 10.3969/j.issn.1000-6621.2014.09.017
Clinic Society of Chinese Antituberculosis Association. Annual report on clinical diagnosis and treatment progress of tuberculosis (2013) (Part 2 clinical treatment)[J]. Chinese Journal of Antituberculosis, 2014, 36(9): 830-854. doi: 10.3969/j.issn.1000-6621.2014.09.017
[1]Palomino JC, Martin A.TMC207 becomes bedaquiline, a new anti-TB drug.Future Microbiol, 2013,8(9):1071-1080.[2]Wong EB, Cohen KA, Bishai WR. Rising to the challenge: new therapies fortuberculosis.Trends Microbiol, 2013,21(9):493-501.[3]Chahine EB, Karaoui LR, Mansour H. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.Ann Pharmacother,2014,48(1):107-115.[4]World Health Organization.The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: Interim policy guidance. Geneva: World Health Organization,2013.[5]Centers for Disease Control and Prevention.Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.MMWR Recomm Rep,2013,62(RR-09):1-12.[6]Dawson R, Diacon A. PA-824, moxifloxacin and pyrazinamide combination therapy for tuberculosis. Expert Opin Investig Drugs, 2013,22(7):927-932.[7]Winter H, Egizi E, Erondu N, et al.Evaluation of pharmacokinetic interaction between PA-824 and midazolam in healthy adult subjects.Antimicrob Agents Chemother, 2013,57(8):3699-3703.[8]Skripconoka V, Danilovits M, Pehme L, et al.Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J,2013,41(6):1393-1400.[9]Zhang Q, Liu Y, Tang S,et al.Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China.Cell Biochem Biophys,2013, 67(3):957-963.[10]Tahlan K, Wilson R, Kastrinsky DB, et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2012,56(4):1797-1809.[11]Lechartier B, Hartkoorn RC, Cole ST. In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2012,56(11):5790-5793.[12]Jawahar MS, Banurekha VV, Paramasivan CN, et al. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients.PLoS One,2013,8(7):e67030.[13]Chang KC, Yew WW, Cheung SW, et al. Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis? Antimicrob Agents Chemother, 2013,57(7):3445-3449.[14]Cox H, Ford N, Hughes J, et al.Linezolid for multidrug-resistant tuberculosis. Lancet Infect Dis, 2013,13(1):16.[15]Roongruangpitayakul C, Chuchottaworn C. Outcomes of MDR/XDR-TB patients treated with linezolid: experience in Thailand. J Med Assoc Thai,2013, 96(10):1273-1282.[16]De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J,2013,41(6):1386-1392.[17]Yoo JW, Lyu J, Lee SD,et al. Clinical experience of using clofazimine to treat multidrug-resistant tuberculosis. Int J Tuberc Lung Dis,2013,17(9):1243-1244.[18]Dey T, Brigden G, Cox H, et al. Outcomes of clofazimine for the treatment of drug resistant tuberculosis: a systematic review and meta-analysis. J AntimicrobChemother,2013, 68(2):284-293.[19]雷建平,涂荣耀.含氯法齐明联合方案治疗耐多药结核疗效分析.江西医药,2013,48(8):674-752.[20]van Toorn R, SchaafHS, Laubscher JA, et al. Short intensified treatment in children with drug-susceptible tuberculous meningitis. Pediatr Infect Dis J, 2014, 33(3):248-252.[21]Efremenko YV, Butov DA, Prihoda ND, et al. Randomized, placebo-controlled phase Ⅱ trial of heat-killed Mycobacterium vaccae (Longcom batch) formulated as an oral pill (V7).Hum Vaccin Immunother, 2013, 9(9):1852-1856.[22]Butov DA, Efremenko YV, Prihoda ND,et al. Randomized, placebo-controlled Phase Ⅱ trial of heat-killed Mycobacterium vaccae (Immodulon batch) formulated as an oral pill (V7).Immunotherapy, 2013, 5(10):1047-1054.[23]Tian WW, Wang QQ, Liu WD, et al. Mycobacterium marinum: a potential immunotherapy for Mycobacterium tuberculosis infection. Drug Des Devel Ther, 2013, 7: 669-680.[24]Alvarez N, Otero O, Camacho F,et al. Passive administration of purified secretory IgA from human colostrum induces protection against Mycobacterium tuberculosis in a murine model of progressive pulmonary infection. BMC Immunol, 2013,14 Suppl 1:S3.[25]吴碧彤,谭守勇,蔡智群,等.母牛分枝杆菌菌苗免疫辅助治疗老年初治空洞型肺结核的疗效分析.临床肺科杂志, 2013,18(7):1267-1269.[26]丁毅. 胸腺五肽对初治肺结核患者免疫功能和痰菌阴转率的影响.临床肺科杂志,2013,18(12):2176-2177.[27]曾熙玲,初乃惠,刘志敏. 耐药结核病辅助治疗的进展. 结核病与肺部健康杂志,2013,2(4):222-227.[28]Meyer J, Harris SA, Satti I,et al. Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery. Vaccine, 2013, 31(7):1026-1033.[29]Tameris M,McShane H, McClain JB, et al. Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG. Tuberculosis (Edinb), 2013, 93(2):143-149.[30]Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previou-sly vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet, 2013, 381(9871):1021-1028.[31]Rowland R, Pathan AA, Satti I, et al. Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial. Hum Vaccin Immunother, 2013, 9(1):50-62.[32]Coler RN, Bertholet S, Pine SO, et al. Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J Infect Dis, 2013, 207(8):1242-1252.[33]Dhanasooraj D, Kumar RA, Mundayoor S. Vaccine delivery system for tuberculosis based on nano-sized hepatitis B virus core protein particles. Int J Nanomedicine, 2013,8:835-843.[34]Feng G, Jiang Q, Xia M, et al. Enhanced immune response and protective effects of nano-chitosan-based DNA vaccine encoding T cell epitopes ofEsat-6 and FL against Mycobacterium tuberculosis infection. PLoS One, 2013, 8(4):e61135.[35]Mohamud R, Azlan M, Yero D, et al. Immunogenicity of recombinant Mycobacterium bovis bacille Calmette-Guèrin clones expressing T and B cell epitopes of Mycobacterium tuberculosis antigens. BMC Immunol,2013,14 Suppl 1:S5.[36]Lakshmi PS, Verma D, Yang X, et al. Low cost tuberculosis vaccine antigens in capsules: expression in chloroplasts, bio-encapsulation, stability and functional evaluation in vitro. PLoS One, 2013,8(1):e54708.[37]Betts G, Poyntz H, Stylianou E,et al. Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expres-sing the mycobacterial antigen Ag85A in a single injection. PLoS One, 2012, 7(12):e50447.[38]Cervantes-Villagrana AR, Hernández-Pando R, Biragyn A, et al. Prime-boost BCG vaccination with DNA vaccines based in β-defensin-2 and mycobacterial antigens ESAT6 or Ag85B improve protection in a tuberculosis experimental model. Vaccine, 2013, 31(4):676-684.[39]Grode L, Ganoza CA, Brohm C, et al. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine, 2013,31(9):1340-1348.[40]Spertini F, Audran R, Lurati F, et al. The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a rando-mized controlled phase Ⅰ/Ⅱ study. Tuberculosis (Edinb), 2013, 93(2):179-188.[41]Skerry C, Pokkali S, Pinn M, et al. Vaccination with recombinant Mycobacterium tuberculosis PknD attenuates bacterial dissemination to the brain in guinea pigs. PLoS One, 2013, 8(6):e66310.[42]Chauhan P, Jain R, Dey B, et al. Adjunctive immunotherapy with α-crystallin based DNA vaccination reduces Tuberculosis chemotherapy period in chronically infected mice. Sci Rep, 2013, 3:1821.[43]de los Angeles García M, Borrero R, Marrón R, et al. Evaluation of specific humoral immune response and cross reactivity against Mycobacterium tuberculosis antigens induced in mice immunized with liposomes composed of total lipids extracted from Mycobacterium smegmatis. BMC Immunol,2013,14 Suppl 1:S11.[44]Borrero R, García Mde L, Canet L, et al. Evaluation of the humoral immune response and cross reactivity against Mycobacterium tuberculosis of mice immunized with liposomes containing glycolipids of Mycobacterium smegmatis. BMC Immunol,2013,14 Suppl 1:S13.[45]Ahn SS, Jeon BY, Park SJ, et al. Nonlytic Fc-fused IL-7 sy-nergizes with Mtb32 DNA vaccine to enhance antigen-specific T cell responses in a therapeutic model of tuberculosis. Vaccine, 2013, 31(27):2884-2890.[46]Dhakal J, Brah GS, Agrawal RK, et al. Over-expression of gene encoding heat shock protein 70 from Mycobacterium tuberculosis and its evaluation as vaccine adjuvant. Indian J Med Microbiol, 2013, 31(2):123-129.[47]Shanley CA, Ireton GC, Baldwin SL, et al. Therapeutic vaccination against relevant high virulence clinical isolates of Mycobacterium tuberculosis. Tuberculosis (Edinb),2014,94(2):140-147.[48]丁卫民, 傅瑜. 关于“气管支气管结核诊断和治疗指南(试行)”的几点补充说明. 中华结核和呼吸杂志, 2013,36(2):159-160.[49]卢晔, 叶惠龙, 崔会芳, 等. “气管支气管结核诊断和治疗指南(试行)”一文读后有感. 中华结核和呼吸杂志, 2013,36(2):159-160.[50]王慧, 傅满姣. 气道球囊扩张治疗结核性气管狭窄的疗效分析.中国内镜杂志,2013,19(7):763-766.[51]LIU WM, DAI L, LIN YH. The efficacy of microwave therapy via bronchofiberscope in the treatment of severe trachea stenosis. J Innov Opt Health Sci, 6:1350006-1-6.[52]Rabieh M. M Hussein a, Emad El-Dine A Korraa b, M Amany Fawzy, et al. Prognostic factors for bronchoscopic electrocautery and/or argon plasma coagulation in patients with central airway obstruction. Egyptian Journal of Chest Diseases and Tuberculosis, 2013, 62: 501-511.[53]Bezzi M. Reopening the airway: Fast methods—laser-assisted mechanical resection, electrocautery, and argon plasma coagulation//Díaz-Jimenez JP, Rodriguez AN. Interventions in pulmonary medicine. Berlin: Springer,2013:99-121.[54]Miller SM, Bellinger CR, Chatterjee A. Argon plasma coagulation and electrosurgery for benign endobronchial tumors. J Bronchology Interv Pulmonol,2013,20(1):38-40.[55]Yun SC, Na MJ, Choi E,et al. Successful removal of endobronchial lipoma by flexible bronchoscopy using electrosurgical snare. Tuberc Respir Dis (Seoul), 2013,74(2):82-85.[56]Jin F, Mu D, Xie Y, et al. Application of bronchoscopic argon plasma coagulation in the treatment of tumorous endobronchial tuberculosis: historical controlled trial. J Thorac Cardiovasc Surg, 2013,145(6):1650-1653.[57]崔嘉,徐建华,刘福升,等. 经支气管镜介入治疗气管支气管结核的近期临床效果初步分析.中国防痨杂志,2013,35(12):1020-1024.[58]Majid A, Palkar A, Myers R,et al. Cryotechnology for staged removal of self-expandable metallic airway stents. Ann Thorac Surg,2013,96(1):336-368.[59]Chou CL, Wang CW, Lin SM,et al. Role of flexible bronchoscopic cryotechnology in diagnosing endobronchial masses. Ann Thorac Surg,2013,95(3):982-986.[60]张杰, 孔颖颖. 喷射冷冻技术在气道腔内疾病中的应用现状及展望. 中华结核和呼吸杂志, 2013,36(9):644-645.[61]Eom JS, Kim H, Jeon K, et al.Tracheal wall thickening is associated with the granulation tissue formation around silicone stents in patients with post-tuberculosis tracheal stenosis. Yonsei Med J, 2013, 54(4):949-956.[62]Eom JS, Kim H, Park HY, et al. Timing of silicone stent removal in patients with post-tuberculosis bronchial stenosis. Ann Thorac Med,2013,8(4):218-223.[63]陆瑶,何元兵,齐曼古力·吾守尔,等. 支气管镜下冷冻结合球囊扩张治疗支气管结核所致气道狭窄24例. 中国内镜杂志,2013,19(4):763-766.[64]Fu EQ, Nan YD, Jin FG, et al. Therapeutic effects of sequential therapy by electric coagulation, cryotherapy and balloon dilation with an electronic video bronchoscope. Exp Ther Med,2013,5(6):1649-1656.[65]苏柱泉,魏晓群,钟长镐,等.良性气管狭窄158例病因及介入治疗疗效分析.中华结核和呼吸杂志,2013, 36 (9):651-654.[66]王利换,张杰,陈楠, 等. 局部应用紫杉醇抑制兔气管损伤后瘢痕组织形成的初步研究. 中华结核和呼吸杂志,2013,36(3):202-206.[67]苗雅. 布地奈德吸入辅助治疗支气管结核的临床疗效观察. 中国防痨杂志,2013,35(2):151-152.[68]Tscheikuna J, Disayabutr S, Kakanaporn C, et al. High dose rate endobronchial brachytherapy(HDR-EB) in recurrent benign complex tracheobronchial stenosis: experience in two cases. J Med Assoc Thai,2013,96 Suppl 2: S252-256.[69]李亮, 李琦, 许绍发,等. 结核病治疗学.北京: 人民卫生出版社, 2013:221-230.[70]Sung N, Back S, Jung J, et al. Inactivation of multidrug resistant (MDR)- and extensively drug resistant (XDR)-Mycobacterium tuberculosis by photodynamic therapy. Photodiagnosis Photodyn Ther,2013,10(4):694-702.[71]雷霆, 缪李丽. 纤维支气管镜介导治疗耐多药肺结核的临床分析. 第三军医大学学报, 2013,35(6):573-575.[72]Wang TK, Oh T, Windsor J, et al. Facilitating synchronous operations with video-assisted thoracoscopic lobectomy. Ann Thorac Surg, 2013,96(5):1912.[73]金发光.内科胸腔镜及其临床应用现状.中国实用内科杂志,2013,33(2):113-115.[74]井晓婷,叶贤伟,金艳坤,等.胸腔镜下介入治疗结核性包裹性胸腔积液的临床疗效.中华医学会呼吸病学年会-第十四次全国呼吸病学学术会议论文汇编.大连,2013.北京:中华医学会呼吸病学分会组委会,2013:360-360.[75]王述桃. 局麻下胸腔镜治疗结核性包裹性胸膜炎的疗效分析. 临床肺科杂志, 2013,18(11):2053-2054.[76]王洪武, 李冬妹, 张楠, 等. 气管内覆膜金属支架置入治疗食管气管瘘. 中华结核和呼吸杂志,2013,36(5):390-392.[77]朱强, 臧琦, 蒋仲敏, 等.全覆膜自膨胀金属支架在气管瘘中的临床应用. 中华结核和呼吸杂志,2013,36(6):431-436.[78]Bertolaccini L,Viti A,Di Perri G,et al. Surgical treatment of pulmonary tuberculosis: the phoenix of thoracic surgery? J Thorac Dis,2013,5(2):198-199.[79]Marrone MT, Venkataramanan V, Goodman M,et al.Surgical interventions for drug-resistant tuberculosis: a systematic review and meta-analysis.Int J Tuberc Lung Dis, 2013,17(1):6-16.[80]Chan ED, Iseman MD. Surgery for MDR-TB? Int J Tuberc Lung Dis, 2013,17(5):710.[81]Xie B, Yang Y, He W,et al.Pulmonary resection in the treatment of 43 patients with well-localized, cavitary pulmonary multidrug-resistant tuberculosis in Shanghai.Interact Cardiovasc Thorac Surg,2013,17(3):455-459.[82]Vashakidze S, Gogishvili S, Nikolaishvili K,et al.Favorable outcomes for multidrug and extensively drug resistant tuberculosis patients undergoing surgery.Ann Thorac Surg, 2013,95(6):1892-1898.[83]Bouchikh M, Achir A, Caidi M, et al. Role of pulmonary resections in management of multidrug-resistant tuberculosis. A monocentric series of 29 patients. Rev Pneumol Clin,2013,69(6):326-330.[84]叶嗣宽,赵攀,杨传利,等.耐多药肺结核早期外科治疗的临床效果分析.第三军医大学学报,2013,35(7):685-687.[85]张嘉利,李大伟,马远征,等.多节段胸腰椎脊柱结核外科治疗的回顾性研究.中国防痨杂志,2013,35(5):305-308.[86]He M, Xu H, Zhao J, et al. Anterior debridement, decompression, bone grafting, and instrumentation for lower cervical spine tuberculosis. Spine J,2014,14(4):619-627.[87]Jin W, Wang Q, Wang Z, et al. Complete debridement for treatment of thoracolumbar spinal tuberculosis: a clinical curative effect observation. Spine J,2014,14(6):964-970.[88]Chandra SP, Singh A, Goyal N, et al. Analysis of changing paradigms of management in 179 patients with spinal tuberculosis over a 12-year period and proposal of a new management algorithm. World Neurosurg,2013,80(1/2):190-203.[89]兰汀隆,秦世炳,董伟杰,等. 一期开胸病灶清除加椎弓根固定治疗儿童胸椎结核35例分析. 中国防痨杂志,2013,35(5):314-316.[90]Zhang HQ, Lin MZ, Guo HB, et al. One-stage surgical ma-nagement for tuberculosis of the upper cervical spine by poste-rior debridement,short-segment fusion,and posterior instrumentation in children. Eur Spine J,2013,22(1):72-78.[91]Tian Y, Shen X, Wang X,et al. Tuberculosis of the lower cervical spine (C5-C6) in a 24-month-old infant. Spine J,2013,13(8):e17-20.[92]黄迅悟,冯会成,孙继桐,等.活动性髋关节结核一期病灶清除全髋关节置换28例报告.中华骨科杂志,2013,33(5):495-500.[93]孙雯雯,吴福蓉,肖和平,等.强化期含左氧氟沙星方案保守治疗脊柱结核的近期疗效分析.中国防痨杂志,2013,35(10):840-842.[94]秦世炳,董伟杰,兰汀隆,等.128例脊柱结核耐药患者的临床分析.中国防痨杂志,2013,35(5): 299-304.[95]李力韬,马远征,李大伟,等.21例耐多药脊柱结核手术联合个体化化疗的临床分析. 中国防痨杂志,2013,35(5): 317-321.[96]秦世炳,宋言峥,董伟杰.骨关节结核临床诊断与治疗进展及其规范化专题研讨会纪要.中国防痨杂志,2013,35(1): 81-84.[97]Yang L, Liu Z.Analysis and therapeutic schedule of the pos-toperative recurrence of bone tuberculosis.J Orthop Surg Res,2013,8:47.[98]陈少健, 肖增明,罗红艳,等.脊柱结核术后复发因素COX 回归分析.航空航天医学杂志,2013,24(9):1055-1057.[99]Rodriguez M,Monedero I,Caminero JA,et al.Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic. Int J Tuberc Lung Dis,2013,17(4):520-525.[100]刘金玲,罗凯,崔兰英.标准化疗方案治疗耐多药肺结核的疗效分析.当代医学,2013,19(16):77.[101]Jiang RH, Xu HB, Li L. Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study. Int J Antimicrob Agents, 2013,42(1):36-41.[102]Koh WJ,Lee SH,Kang YA,et al. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis.Am J Respir Crit Care Med,2013,188(7):858-864.[103]Seung KJ,Becerra MC,Atwood SS,et al. Salvage therapy for multidrug-resistant tuberculosis. Clin Microbiol Infect,2014,20(5):441-446.[104]李学玲,陈晓红,林忠惠,等.莫西沙星与左氧氟沙星治疗耐多药肺结核疗效对比研究. 北京医学,2013,35(9):764-766.[105]童海娟,程毅,谭川. 氟喹诺酮类药物治疗耐多药结核病临床疗效研究.中国伤残医学,2013,21(7):48-49.[106]Chang KC, Yew WW, Tam CM,et al.WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis.Antimicrob Agents Chemother, 2013,57(9):4097-4104.[107]苗雅.阿莫西林克拉维酸钾联合丙硫异烟胺治疗耐多药肺结核临床疗效分析.中国保健营养,2013,4(4):369-370.[108]Hoppentocht M, Hagedoorn P, Frijlink HW, et al. Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: a critical evaluation. Eur J Pharm Biopharm,2014,86(1):23-30.[109]Ordonez AA, Maiga M, Gupta S,et al. Novel adjunctive therapies for the treatment of tuberculosis.Curr Mol Med,2014,14(3):385-395.[110]Carroll MW, Jeon D, Mountz JM, et al. Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis. Antimicrob Agents Chemother, 2013,57(8):3903-3909.[111]Zheng M,Jin H,Fu L,et al. A comparative study on the activities of six combination regimens against multidrug-resis-tant Mycobacterium tuberculosis infection in BALB/c mice. J Chemother,2013,25(2):81-86.[112]Ribeiro Macedo L, Reis-Santos B, Riley LW, et al. Treatment outcomes of tuberculosis patients in Brazilian prisons: a polytomous regression analysis.Int J Tuberc Lung Dis, 2013,17(11):1427-1434.[113]Ahmed MM,Mohammed SH,Nasurallah HA. Mutation in katG315 is, possibly, a good prognostic marker for treatment with second-line drugs in multi-drug resistant tuberculosis: a preliminary study.Indian J Med Microbiol, 2013,31(4):395-400.[114]Kang YA, Kim SY, Jo KW,et al. Impact of diabetes on treatment outcomes and long-term survival in multidrug-resistant tuberculosis. Respiration, 2013,86(6):472-478.[115]Shean K, Streicher E, Pieterson E, et al. Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa. PLoS One, 2013, 8(5):e63057.[116]Unsal E, Güler M, Ofluoglu R, et al. Factors associated with treatment outcome in 64 HIV negative patients with multidrug resistant tuberculosis.J Thorac Dis, 2013,5(4):435-439.[117]Unsematham S, Kateruttanakul P. Factors predicting sputum smear conversion and treatment outcomes in new smear-positive pulmonary tuberculosis. J Med Assoc Thai, 2013,96(6):644-649.[118]Mitnick CD, Franke MF, Rich ML,et al. Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality. PLoS One, 2013,8(3):e58664.[119]Isaakidis P, Paryani R, Khan S, et al. Poor outcomes in a cohort of HIV-infected adolescents undergoing treatment for multidrug-resistant tuberculosis in Mumbai.PLoS One, 2013,8(7):e68869.[120]O’Donnell MR, Padayatchi N, Kvasnovsky C,et al. Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis, 2013,19(3):416-424.[121]Seddon JA, Hesseling AC, Godfrey-Faussett P, et al. High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. Thorax, 2014,69(5):458-464.[122]Fenner L, Reid SE, Fox MP, et al. Tuberculosis and the risk of opportunistic infections and cancers in HIV-infected patients starting ART in Southern Africa. Trop Med Int Health, 2013,18(2):194-198.[123]WHO. Global tuberculosis report 2013 [M/OL].Genava:WHO,2013[2014-01-23].http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf?ua=1.[124]Cortes CP, Wehbe FH, McGowan CC, et al. Duration of anti-tuberculosis therapy and timing of antiretroviral therapy ini-tiation: association with mortality in HIV-related tuberculosis.PLoS One, 2013,8(9):e74057.[125]World Health Organization. WHO policy on collaborative TB/HIV activities Guidelines for national programmes and other stakeholders. Genava: World Health Organization,2012.[126]Durovni B, Saraceni V, Moulton LH, et al. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis, 2013,13(10):852-858.[127]Rangaka MX, Wilkinson RJ. Isoniazid prevention of HIV-associated tuberculosis. Lancet Infect Dis,2013,13(10):825-827.[128]Sibanda T, Tedla Z, Nyirenda S, et al. Anti-tuberculosis treatment outcomes in HIV-infected adults exposed to isoniazid preventive therapy in Botswana. Int J Tuberc Lung Dis,2013,17(2):178-185.[129]Gray JM, Cohn DL. Tuberculosis and HIV coinfection. Semin Respir Crit Care Med,2013,34(1):32-43.[130]Lahey T, MacKenzie T, Arbeit RD, et al. Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis.Clin Infect Dis, 2013,56(1):151-158.[131]Wejse C, Furtado A, Camara C, et al. Impact of tuberculosis treatment on CD4 cell count, HIV RNA, and p24 antigen in patients with HIV and tuberculosis. Int J Infect Dis, 2013,17(10):e907-912.[132]Nakiyingi L, Bwanika JM, Kirenga B, et al. Clinical predictors and accuracy of empiric tuberculosis treatment among sputum smear-negative HIV-infected adult TB suspects in Uganda. PLoS One, 2013,8(9):e74023.[133]Chu R, Mills EJ, Beyene J, et al. Impact of tuberculosis on mortality among HIV-infected patients receiving antiretroviral therapy in Uganda: a prospective cohort analysis. AIDS Res Ther,2013,10(1):19.[134]Ahmad Khan F, Minion J, Al-Motairi A, et al. An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection. Clin Infect Dis, 2012,55(8):1154-1163.[135]Ismail I, Bulgiba A. Predictors of death during tuberculosis treatment in TB/HIV co-infected patients in Malaysia. PLoS One, 2013,8(8):e73250.[136]Stockdale AJ, Nkuranga J,Trk ME, et al. Initiation of antiretroviral therapy in HIV-infected tuberculosis patients in rural Kenya: an observational study. Trop Med Int Health,2013,18(7):907-914.[137]dos Santos AP, Pacheco AG, Staviack A, et al. Safety and effectiveness of HAART in tuberculosis-HIV co-infected patients in Brazil. Int J Tuberc Lung Dis,2013,17(2):192-197.[138]Gervasoni C, Riva A, Impagnatiello C, et al. Is chewed raltegravir an option to care for HIV-infected patients with active tuberculosis?Clin Infect Dis, 2013,57(3):480-481.[139]van Dijk JH, Sutcliffe CG, Hamangaba F, et al. Effectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings. PLoS One, 2013,8(1):e55111.[140]Bonnet M, Bhatt N, Baudin E, et al. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. Lancet Infect Dis, 2013,13(4):303-312.[141]Narendran G, Andrade BB, Porter BO, et al. Paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in HIV patients with culture confirmed pulmonary tuberculosis in India and the potential role of IL-6 in prediction. PLoS One, 2013,8(5):e63541.[142]Oliver BG, Haddow LJ, Agarwal U, et al. Pre-antiretroviral therapy plasma levels of CCL2 may aid in the prediction of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV patients after they commence antiretroviral therapy. J Acquir Immune Defic Syndr, 2013,63(2):e72-74.[143]李永文,李新旭,耿红. 山东省结核分枝杆菌的耐药流行状况.中华结核和呼吸杂志,2013,36(9):667-670.[144]Tuberculosis Surveillance Center,RIT, JATA.Tuberculosis Annual Report 2011--(2) Childhood and elderly tuberculosis.Kekkaku,2013,88(7):611-616.[145]Patra S, Lukhmana S,Tayler Smith K,et al.Profile and treatment outcomes of elderly patients with tuberculosis in Delhi, India: implications for their management. Trans R Soc Trop Med Hyg,2013,107(12):763-768.[146]Mamo JP, Brij SO. Treating tuberculosis in the elderly population: a lesson in multi-disciplinary care. Scott Med J, 2013,58(4):e15-16.[147]Chang CH,Chen YF,Wu VC,et al. Acute kidney injury due to anti-tuberculosis drugs: a five-year experience in an aging population. BMC Infect Dis, 2014,14:23.[148]戈启萍,王庆枫,段鸿飞,等.含丙硫异烟胺和对氨基水杨酸治疗方案发生药物性肝损伤129例临床分析.中华结核和呼吸杂志,2013,36(10):737-739.[149]Paterson JM, Mamdani MM,Manno M, et al.Fluoroquino-lone therapy and idiosyncratic acute liver injury: a population-based study.CMAJ,2012,184(14):1565-1570.[150]Miyazawa N, Horita N, Tomaru K,et al.Comparison of drug-induced hepatitis occurring in elderly and younger patients during anti-tuberculosistreatment with a regimen including pyrazinamide. Kekkaku, 2013,88(3):297-300.[151]朱路平,罗君,李喜.利福喷丁与利福平在治疗肺结核中的临床疗效分析.中国实用医药,2012,7(28):146-147.[152]Morimoto K,Yoshiyama T, Kuse M, et al. Clinical ex-perience using rifabutin for treating infection with Mycobacterium tuberculosis in elderly Japanese patients. Kekkaku, 2013,88(8):625-628.[153]An JY, Li DW, Cui X,et al.Analysis of clinical characteristics of elderly patients with spinal tuberculosis and its clinical effects with conservative treatment. Zhongguo Gu Shang, 2013,26(3):210-213.[154]王仲元,苏锐,安慧茹,等. 老年肺结核643例的临床特点.中华结核和呼吸杂志,2013,35(3):213-214.[155]Mamo JP, Brij SO. Treating tuberculosis in the elderly population: a lesson in multi-disciplinary care. Scott Med J,2013,58(4):e15-16.[156]Miyata S, Tanaka M, Ihaku D. Full mini nutritional assessment and prognosis in elderly patients with pulmonary tuberculosis.J Am Coll Nutr,2013,32(5):307-311.[157]Garazzino S, Scolfaro C, Raffaldi I,et al. Moxifloxacin for the treatment of pulmonary tuberculosis in children: a single center experience. Pediatr Pulmonol,2014,49(4):372-376.[158]Rose PC, Hallbauer UM, Seddon JA,et al. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children. Int J Tuberc Lung Dis,2012,16(12):1588-1593.[159]Chiappini E, Sollai S, Bonsignori F, et al. Controversies in preventive therapy for children contacts of multidrug-resistant tuberculosis. J Chemother, 2014,26(1):1-12.[160]Seddon JA, Hesseling AC, Finlayson H,et al. Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study. Clin Infect Dis, 2013,57(12):1676-1684.[161]Taylor AW, Mosimaneotsile B, Mathebula U,et al. Pregnancy outcomes in HIV-infected women receiving long-term isoniazid prophylaxis for tuberculosis and antiretroviral therapy. Infect Dis Obstet Gynecol, 2013,195637.[162]Ard KL, Chan BT, Milner DA Jr, et al. Peritoneal Tuberculosis in a Pregnant Woman from Haiti, United States. Emerg Infect Dis,2013,19(3): 514-516.[163]Veerappan I, Shanmugam A, Kumar S,et al. Bilateral psoas and bilateral perinephric abscesses comp licating acute pyelonephritis in pregnancy. Indian J Nephrol, 2013,23(1): 59-62.[164]Bishara H, Vinitsky O, Salim R, et al. Tuberculosis in pregnancy and puerperium. Harefuah, 2013,152(7):381-384.[165]Nakbanpot S, Rattanawong P. Congenital tuberculosis because of misdiagnosed maternal pulmonary tuberculosis during pregnancy. Jpn J Infect Dis, 2013,66(4):327-330.[166]Desai M, Phillips-Howard PA, Odhiambo FO, et al. An analysis of pregnancy-related mortality in the KEMRI/CDC health and demographic surveillance system in western Kenya. PLoS One,2013,8(7):e68733.[167]吴同柱,朱木新.38例妊娠合并结核病误诊原因分析.临床肺科杂志,2013,18(4):716-717.[168]中华医学会消化病学分会肝胆协作组.急性重症药物性肝损伤全国多中心调查分析.中华消化杂志,2013,33(2):80-83.[169]Palmero D, Castagnino J, Musella RM, et al. Difficult clinical management of anti-tuberculosis DRESS syndrome. Int J Tuberc Lung Dis,2013,17(1):76-78.[170]Horita N, Miyazawa N, Yoshiyama T, et al. Decreased activities of daily living is a strong risk factor for liver injury by anti-tuberculosis drugs. Respirology, 2013,18(3):474-479.[171]Kato H, Horita N, Miyazawa N, et al. Risk factors for liver injury with an elevated serum bilirubin concentration caused by antituberculous drugs. Intern Med, 2013,52(19):2209-2214.[172]Devarbhavi H, Singh R, Patil M, et al. Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury. J Gastroenterol Hepatol, 2013,28(1):161-167.[173]Hassen Ali A, Belachew T, Yami A, et al. Anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control study.PLoS One, 2013,8(5):e64622.[174]张金玲,朱学彬,李世明,等.SLCO1B1/ABCB1基因多态性与抗结核药物性肝损伤的相关性分析.中华疾病控制杂志,2013,6(6):469-471.[175]Li C, Long J, Hu X, et al. GSTM1 and GSTT1 genetic po-lymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: an updated meta-analysis. Eur J Clin Microbiol Infect Dis,2013,32(7):859-868.[176]Tang N, Deng R, Wang Y, et al. GSTM1 and GSTT1 null polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis,2013,17(1):17-25.[177]Du H, Chen X, Fang Y, et al. Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis. Mol Biol Rep, 2013,40(5):3591-3596.[178]Azuma J, Ohno M, Kubota R, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol, 2013,69(5):1091-1101.[179]顾瑾,肖和平.抗结核药所致肝损伤防治的研究进展.中华结核和呼吸杂志,2013,36(10):767-769.[180]中华医学会结核病学分会,《中华结核和呼吸杂志》编辑委员会.抗结核药所致药物性肝损伤诊断与处理专家建议. 中华结核和呼吸杂志,2013,36(10):732-736.[181]陈成伟.药物性肝损伤的发病机制及其处理. 中华结核和呼吸杂志,2013,36(10):726-728.[182]徐张巍,李杨,许建明. 抗结核药物性肝损伤适应现象的临床研究. 中华肝脏病杂志,2013, 21(9):697-700.[183]Liu CT, Chen TH, Cheng CY.Successful treatment of drug-induced acute liver failure with high-volume plasma exchange. J Clin Apher,2013,28(6):430-434.[184]罗敬福.复方甘草酸苷联合双环醇治疗抗结核药所致药物性肝炎36例.中国医学前沿杂志(电子版),2013,5(11):35-37.[185]傅祖红,姚行齐,胡振红,等.甘草酸二胺注射液治疗抗结核药物性肝损害的疗效观察.中国医院药学杂志,2003,23(12):749.[186]舒德云.双环醇治疗抗结核药物所致肝损伤的临床分析.现代诊断与治疗,2013,24(10):2209-2210.[187]肖和平.抗结核治疗时预防性保肝用药的是与非. 中华结核和呼吸杂志,2013,36(10):722-723.[188]马玙,卜建玲,陈效友.重视抗结核药物性肝损伤. 中华结核和呼吸杂志,2013,36(10):723-725.[189]缪晓辉.如何防护抗结核药所致肝损伤. 中华结核和呼吸杂志,2013,36(10):729-731.[190]周殷. 复方甘草酸苷联合还原型谷胱甘肽预防抗结核药物致肝损害效果观察. 现代仪器与医疗,2013,19(3):74-76.[191]乐海鹰,张敏,王丽英.甘草酸二铵肠溶胶囊预防抗结核药物性肝损伤疗效观察.上海中医药杂志,2013,47(2):51-52.[192]何荣梅.双环醇预防抗结核药物致肝损伤的疗效分析.内蒙古中医药,2013,(13):15-16. |
[1] | 马廷龙, 韩毅, 程序, 刘志东. 超声抗结核药品电导入联合化疗对胸壁结核的疗效观察[J]. 中国防痨杂志, 2020, 42(9): 968-972. |
[2] | 首都医科大学附属北京胸科医院 中国防痨协会非结核分枝杆菌分会 《中国防痨杂志》编辑委员会. 非结核分枝杆菌病治疗药品超说明书用法专家共识[J]. 中国防痨杂志, 2020, 42(8): 769-787. |
[3] | 盛杰, 朱洋, 地里下提·阿不力孜, 唐伟, 古甫丁, 宋兴华. 表型与分子药物敏感性试验对术后耐药骨关节结核患者化疗的指导与效果分析[J]. 中国防痨杂志, 2020, 42(8): 838-844. |
[4] | 王倪, 张慧, 张铁娟, 陈彬, 雷娟, 孙苗苗, 黄飞. 使用电子药盒辅助肺结核患者服药管理的实施情况分析[J]. 中国防痨杂志, 2020, 42(7): 682-686. |
[5] | 谢莉, 高静韬, 马丽萍, 张立群, 孔忠顺, 吴晓光, 刘荣梅, 陈红梅, 宋艳华, 李雪莲, 黄麦玲, 李强, 吕子征, 刘宇红, 高孟秋. 含贝达喹啉方案治疗耐多药肺结核对患者心电图QT间期的影响[J]. 中国防痨杂志, 2020, 42(7): 687-694. |
[6] | 赵本南, 刘大凤, 刘亚玲, 杨铭, 兰丽娟, 杜清. 含丙硫异烟胺和对氨基水杨酸方案治疗耐多药结核病患者致甲状腺功能减退症的临床分析[J]. 中国防痨杂志, 2020, 42(5): 465-471. |
[7] | 邱磊,张少言,郭晓燕,付际游,田黎明,张惠勇,鹿振辉. 化疗方案加芩部丹片治疗复治涂阳肺结核患者的临床价值[J]. 中国防痨杂志, 2020, 42(2): 108-114. |
[8] | 王雪迪,江锋,代倩兰,王京,王冬梅. 中西医联合与单纯西医治疗结核病所致药物性肝损伤的对比分析(2000—2019年文献复习)[J]. 中国防痨杂志, 2020, 42(2): 126-132. |
[9] | 应若嫣, 黄晓辰, 王洁, 刘一典, 沙巍, 杨华. 耐药MTB分离株对不同组合抗结核药品体外药物敏感性试验的结果分析[J]. 中国防痨杂志, 2020, 42(11): 1183-1182. |
[10] | 刘二勇, 周林, 薛晓, 刘春法, 白丽琼, 陆伟, 张天华, 成诗明. 利福平胶囊(Ⅱ)对肺结核治疗效果及安全性研究[J]. 中国防痨杂志, 2020, 42(10): 1092-1099. |
[11] | 李婷婷, 刘欢庆, 杜巧盈. 中药治疗肺结核的用药规律及作用机制预测[J]. 中国防痨杂志, 2020, 42(10): 1115-1120. |
[12] | 刘一典,桂徐蔚,申晓娜,于媛媛,姚岚,楼海,沙巍,肖和平. 2019年《ATS/CDC/ERS/IDSA临床实践指南:耐药结核病治疗》解读及与我国《耐药结核病化学治疗指南(2019年)》对比[J]. 中国防痨杂志, 2020, 42(1): 12-16. |
[13] | 王嘉雯,黄珊珊,刘恺懿,梁鸿迪,冯慧莹,周芳静,梁安棋,陈亮,周琳. 对结核病患者实施移动通信直接面视下短程督导化疗的效果评价[J]. 中国防痨杂志, 2019, 41(9): 946-950. |
[14] | 李雪,姜世闻,胡冬梅,徐彩红,刘小秋. 电子药盒和手机微信APP的应用对肺结核患者服药依从性的效果评价[J]. 中国防痨杂志, 2019, 41(9): 957-961. |
[15] | 张会军,鲁增辉,谭淦文,朱昌生. 耐药脊柱结核术后并发窦道患者实施个体化治疗的临床效果(附24例短期疗效分析)[J]. 中国防痨杂志, 2019, 41(7): 759-764. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||